Delcath Systems, Inc. announced the acceptance of an oral presentation for results from the investigator-initiated CHOPIN randomized Phase 2 trial at the 2025 European Society for Medical Oncology (ESMO) Annual Congress. The presentation is scheduled for Saturday, October 18, 2025.
The data to be presented will evaluate the safety, tolerability, and efficacy of sequencing systemic ipilimumab and nivolumab with Delcath’s CHEMOSAT Hepatic Delivery System for percutaneous hepatic perfusion with melphalan. This study focuses on patients with metastatic uveal melanoma.
Principal Investigator Ellen Kapiteijn, MD, from Leiden University Medical Center, will present the findings. The acceptance of this presentation at a prominent oncology congress highlights the growing body of evidence supporting the hepatic delivery system and its potential in combination therapies for liver-dominant cancers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.